The study aims to confirm the efficacy and safety of erenumab in migraine patients.

Migraine prevention with erenumab is approved in Kuwait. It is a fully human monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr).

This is a prospective, real-life, cohort study. In our tertiary hospital in Kuwait, we selected patients with a ICHD-3 diagnosis of migraine who received erenumab monthly between May 2019 and April 2022. The study included migraine patients aged 18 to 65 years treated with erenumab in the Headache clinic. Primary endpoint of this analysis was the mean change in monthly headache days from the baseline until the end of observational period. Secondary endpoints were changes days with acute headache medication in the treatment period, severity of headache pain and change of quality of after treatment.

A total of 151 migraine patients were identified to the study, 123 (81.5%) were female, with a mean age of 20.23+11.74years. Erenumab decreased mean headache days frequency from 15.05 +  8.93 to 6.08+ 6.05; p<0.002;  mean monthly days of analgesic use from 15.48 +8.77

  to 6.30+ 6.83; P < 0.001), and mean severity of headache pain from 8.75+ 1.67

  to 5.46 +2.90. Constipation (6%) was the most frequent adverse events reported.